Related Experiment Video

Updated: Sep 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins, super-statins and cholesterol absorption inhibitors

Margaret E Brousseau1

  • 1JM-USDA-HNRCA at Tufts University, Lipid Metabolism Laboratory, 711 Washington Street, Boston, MA 02111, USA. margaret.brousseau@tufts.edu

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed

Insights

High LDL-C levels increase coronary heart disease risk. Statins and other drugs effectively lower LDL-C, reducing this risk. This review covers statin trials and new treatments like rosuvastatin, pitavastatin, and ezetimibe.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for premature coronary heart disease (CHD).
  • National Cholesterol Education Program guidelines define high-risk LDL-C levels (> or = 160 mg/dl) and set therapeutic goals based on CHD risk factors.
  • Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) by statins revolutionized the management of hypercholesterolemia.

Purpose of the Study:

  • To review large-scale clinical trials demonstrating the efficacy of statins in reducing LDL-C concentrations.
  • To discuss the effectiveness and safety of emerging LDL-lowering therapies, including super-statins (rosuvastatin, pitavastatin) and ezetimibe.
  • To provide an overview of current treatment strategies for patients with elevated LDL-C.

Main Methods:

  • Review of large-scale clinical trials involving statin therapy for LDL-C reduction.
  • Examination of studies evaluating the efficacy and safety of rosuvastatin, pitavastatin, and ezetimibe.
  • Analysis of data from primary and secondary intervention trials on CHD risk reduction.

Main Results:

  • Statins have demonstrated clear efficacy in lowering LDL-C and reducing CHD risk across numerous trials.
  • Emerging therapies like rosuvastatin, pitavastatin, and ezetimibe offer additional options for managing elevated LDL-C.
  • The efficacy and safety profiles of these newer agents are supported by clinical study data.

Conclusions:

  • Statins are a cornerstone therapy for managing elevated LDL-C and preventing CHD.
  • Rosuvastatin, pitavastatin, and ezetimibe represent important advancements in LDL-lowering treatment options.
  • Effective management of LDL-C is crucial for reducing the burden of cardiovascular disease.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Drug Absorption: Factors Affecting GI Absorption01:19

Drug Absorption: Factors Affecting GI Absorption

The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
In...
Factors Influencing Drug Absorption: Physicochemical Parameters01:22

Factors Influencing Drug Absorption: Physicochemical Parameters

The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...